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Methods: VERIFY Pre-Op TIMI 45 was a prospective study of 42 patients with
indications for coronary angiography subsequently referred for CABG. All patients were
therapeutic on clopidogrel. Platelet function was assessed with VerifyNow™ P2Y12
Reaction Units (PRU). Chest tube output within 24-hours of CABG was stratified by PRU
 208,  230, and  275. Results reported as meanSD.
Results: Median time from last clopidogrel dose to CABG was 4 days (range 1 to 9
days). Patients who held clopidogrel 4 days had lower PRU than those who held for
4 days (19084 vs. 27121 PRU; p0.015). Thresholds of PRU  208 or  275
correlated with less bleeding but did not reach significance (p0.20 and p0.39). Patients
with PRU  230 had significantly less chest tube output than those with PRU  230
(622220 vs. 1028676; p0.026) (Figure).
Conclusions: The VerifyNow™ P2Y12 platelet function assay can be used to predict
perioperative bleeding in patients exposed to clopidogrel undergoing CABG. A threshold
of 230 PRU is associated with less bleeding, and may assist clinicians in optimizing the
timing of surgery.
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Background: High on-treatment platelet reactivity (HPR) has been identified as an
independent risk factor for ischemic events in acute coronary syndrome (ACS) patients
(pts). In TRIPLET, ACS pts undergoing percutaneous coronary intervention (PCI) were
given a prasugrel (pras) loading dose (LD) with or without a prior clopidogrel (clop) LD.
An analysis of HPR was included.
Methods: TRIPLET was a randomized, double-blind study in ACS-PCI pts on aspirin
using VerifyNow P2Y12 assay to evaluate Pras with or without prior Clop in 3 arms: (1)
placebo (PBO) followed by Pras 60-mg LD (2) Clop 600-mg LD followed by Pras 30-mg
LD (3) Clop 600-mg LD followed by Pras 60-mg LD. Pts undergoing PCI received Pras
10-mg once daily (qd) for 2-4 days. HPR (P2Y12 Reaction Units [PRU] 240) were
evaluated in the pharmacodynamic population within 24 hrs following the PBO/Clop LD,
immediately prior to Pras LD and at 2, 6, 24, 72 hrs following Pras LDs.
Results: HPR following Clop was 58.5% in the combined Clop LD arms. No substantial
difference was noted when stratified by time between the Clop and Pras LDs ( 6hrs vs
6 hrs). At 6 hrs in the combined Pras LD arms, HPR was 7.1%, with 0% HPR by 72
hrs. Because a high number of HPR occurred in a single site, a statistical outlier analysis
was performed. When outliers were excluded, HPR occurred in 1.9% at 6 hours and in 0%
by 24 hrs.
Conclusions: In TRIPLET, pts with ACS intended for PCI showed a high prevalence of
HPR after Clop 600-mg LD, even when measured after 6 hrs. When Pras LD was added,
HPR decreased substantially by 6 hrs and was absent by 72 hrs.
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Background: Clopidogrel loading dose of 600mg is used in patients undergoing PCI and
those treated for acute coronary syndromes. 600mg of clopidogrel can significantly inhibit
platelet inhibition within 2 hours but also improve endothelial dysfunction in stable CAD
patients via a mechanism independent of platelet function. We sought to study the effect
of both acute clopidogrel 600mg loading and chronic 75mg therapy on markers of NO
metabolism, vasodilatory effect and antioxidant status in these patients.
Methods: 58 CAD patients were recruited. In the clopidogrel naive group (36 subjects)
blood was taken before and 2h after 600mg dose of clopidogrel and 75mg aspirin
(ASA)who were attending for PCI for stable angina. We studied another cohort on chronic
ASA and clopidogrel 75mg (22 subjects) after 2 months of therapy. All plasma samples
were measured for NO metabolites (nitrite, nitrate and S-nitrosothiols), cGMP (a marker
of vasodilatory effect) and antioxidant capacity of the plasma (ORAC index). Pearson
correlation statistics were performed on all acute pre and post clopidogrel loading and
chronic therapy to explore the relationships seen in NO metabolites.
Results: 2 hours after clopidogrel 600mg dose, plasma nitrite was increased from
157.182.4 to 194.287.64 nM (p0.012), cGMP from 214.2124.4 to 231.5107.8
pmol/ml(p0.05) and ORAC index from 60.6611.45 to 64.1510.61%(p0.037).
Acute loading - the rise in cGMP was inversely related to the total antioxidant capacity
of the plasma (ORAC index)p0.0001 also the rise in nitrite with the increase in cGMP
p0.0043. There was a weaker correlation in the rise in nitrate as a consequence of
600mg with the rise in ORAC p0.0782. After chronic clopidogrel, nitrite was increased
from 157.182.4 to 254.3139.4nM(p0.0028), as well as cGMP from 214.2124.4 to
276.972.15pmol/ml(p0.05). In both acute and chronic groups RSNO (nitrosothiol)
was unchanged.
Conclusions: Patients receiving clopidogrel exhibit a time-proportional increase in NO
bioavailability and effective vasodilation. Clopidogrel has beneficial effects on redox
status 2 hours after 600mg. These results suggest non platelet - pleiotropic effects of
clopidogrel in CAD patients.
TCT-725
Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide
Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel
With High Accuracy in Patients With Coronary Artery Disease
David Erlinge1, Stefan James2, Suman Duvvuru3, Joseph Jakubowski3,
Henrik Wanger4, Christoph Varenhorst2, Udaya Tantry5, Patricia Brown3,
David Small3, Brian Moser3, Scott Sundseth6, Joseph Walker7, Kenneth Winters3,
Paul Gurbel8
1Lund University, Lund, Sweden, 2Uppsala Clinical Research Center, Uppsala,
Sweden, 3Eli Lilly and Company, Indianapolis, IN, 4Region Skåne, Lund, Sweden,
5Sinai Center for Thrombosis Research, Baltimore, MD, 6Cabernet
Pharmaceuticals, Chapel Hill, NC, 7Daiichi Sankyo, Inc., Edison, NJ, 8Sinai
Center for Thrombosis Research, Baltimore, United States
Background: The clinical use of genetic testing in ACS is limited by accessibility and
turn-around-time. Nanosphere Verigene® System is a novel point-of-care (POC) genetic
test analyzing 11 CYP2C19 variants within 3 hours. We evaluated the accuracy of the
method to identify extensive (EM) and reduced clopidogrel (clop) metabolizers (RM) in
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